M:M News

Pathios Therapeutics presents preclinical in vivo proof of concept data for small molecule GPR65 inhibitor in human PDX cancer model

Data highlights the ability of GPR65 inhibition to bring about a robust Type I/II interferon (IFN) gene signature and reduce tumor burden…

Grey Wolf Therapeutics to Present Preclinical Data on First-in-Class ERAP1 Inhibitors at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

New Data Highlight the Potential of Neoantigen-Generating ERAP1 Inhibitors to Drive a Differentiated T Cell Response, Leading to Tumor Growth Inhibition. Proprietary…

Pathios Therapeutics and Sygnature Discovery sign a strategic and innovative partnership

Pathios Therapeutics and Sygnature Discovery sign a strategic and innovative partnership to develop first in class therapies in autoimmune disease and immuno-oncology

Grey Wolf Therapeutics completes £10 million ($14 million) series A financing

Grey Wolf Therapeutics completes £10 million ($14 million) series A financing with Andera Partners and Canaan to fund development of immuno-oncology therapies…